Trusted Press Release Distribution   Join | Login    

Briefing Search
Keyword:
Category:

       

    
Author Details
Credence Research
www.credenceresearch.com/
Chris Smith
sales@credenceresearch.com
18003618290
105 N 1st ST #429, SAN JOSE,, CA 95103, United States
SANJOSE

Bookmark and Share
Atopic Dermatitis (AD) Treatment Market 2025 - CR
Global Atopic Dermatitis (AD) Treatment Market Is Expected To Reach US$ 7.66 Bn By 2025

BriefingWire.com, 8/11/2018 - According to the latest market report published by Credence Research, Inc. “Atopic Dermatitis (AD) Treatment  Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025” the global atopic dermatitis (AD) treatment  market was valued at US$ 4.04 Bn in 2016, and is expected to reach US$ 7.66 Bn by 2025, expanding at a CAGR of  7.4% from 2017 to 2025.

Browse the full report Atopic Dermatitis (AD) Treatment Market - Growth, Future Prospects and Competitive Analysis, 2017 – 2025 at www.credenceresearch.com/report/atopic-dermatitis-ad-treatment-market

Market Insights

Atopic dermatitis is also known as atopic eczema, it is a chronic inflammatory skin disease characterized by itchy skin lesions and rashes. It affects people of all ages but more common among infants and children. Risk factors for atopic dermatitis are mainly categorized as modifiable and non-modifiable. Modifiable risk factors include inhalant and food allergens however, non-modifiable risk factors include genetics or heritability.

For the purpose of the study AD treatment market is segmented on the basis of drug type such as anti-inflammatory agents, antihistamines, immunomodulators, interleukin inhibitors, topical phosphodiesterase-4 (PDE-4) inhibitors, antiviral agents and antibiotics. It is observed that currently anti-inflammatory agents is major revenue generating segment as these drugs are preferably used as a first line therapy after failure of skin care and moisturizers due to its effectiveness.

Strong pipeline molecules such as ABT-494, apremilast, LY-3009104, GSK-2894512, REGN-668, GBR-830, MEDI-9929, nemolizumab, OPA-15406, PF-04965842, secukinumab and tralokinumab are expected to show AD treatment market growth during forecast period 2017-2025. In the base year 2016, North America dominated the global AD treatment market due to large number of target population, higher treatment awareness, swift adoption of novel medications, and better reimbursement policies.

On the other hand, Asia Pacific will show highest AD treatment market growth during forecast period due to increasing healthcare awareness among general population and growing partnership of key players with local manufacturer.

Market Competition Assessment:

The atopic dermatitis (AD) treatment market is observed to be highly competitive and comprises large number of players. However, some major market players are LEO Pharma A/S, AbbVie Inc., Encore Dermatology Inc., F. Hoffmann-La Roche AG, Glaxosmithkline plc., Medimmune (Astrazeneca), Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Valeant Pharmaceuticals Inc. and other.

Browse the full report at www.credenceresearch.com/report/atopic-dermatitis-ad-treatment-market

 
 
FAQs | Contact Us | Terms & Conditions | Privacy Policy
© 2013 Proserve Technology, Inc.